Contacts

 MedinCell announces the availability of its 2021/2022 Universal Registration Document including the Annual Financial Report 

July 29, 2022

MedinCell (FR0004065605 – MEDCL), a pharmaceutical company at premarketing stage developing a portfolio of long-acting injectable products in various therapeutic areas, announces today the filing of its 2021/2022 Universal Registration Document (URD) with the French market authority (Autorités des Marchés Financiers, or AMF) under the reference D.22-0662.
The universal registration document notably includes:
• the annual financial report for the year ending on March 31, 2022;
• the management report;
• the CSR report;
• the report on corporate governance; and
• the proposed text of the resolutions to be submitted to the ordinary and extraordinary Shareholders’ Meeting of September 8, 2022.
This universal registration document may be consulted on the Company’s website (invest.medincell.com), “Investors” section, and on the AMF’s website (www.amf-france.org).

Session en français

Rendez-vous le mardi 14 juin à 18h30 (CEST) pour une vidéoconférence dédiée aux résultas annuel 2021-2022

English session

On Tuesday 14, June at 7.30 pm (CEST) participate in our videoconference dedicated to our Financial year 2021-2022 results

Êtes-vous un actionnaire de MedinCell ? / Are you a MedinCell shareholder?
Vous êtes / You are :
This field is for validation purposes and should be left unchanged.

CONTACT

  • This field is for validation purposes and should be left unchanged.